Cochrane for Clinicians
Putting Evidence into Practice
Pharmacotherapy for Mild Hypertension
Am Fam Physician. 2013 Jul 1;88(1):21.
Does treating mild hypertension improve health outcomes?
Pharmacologic treatment of mild hypertension for up to five years does not reduce coronary events, stroke, or mortality compared with placebo. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
Evidence supporting antihypertensive drug therapy to reduce the incidence of cardiovascular disease events and mortality combines populations of patients with all stages of hypertension, as well as patients with and without previously recognized cardiovascular disease.1 It is unclear whether pharmacotherapy for patients with stage 1 hypertension (i.e., systolic blood pressure of 140 to 159 mm Hg and/or diastolic blood pressure of 90 to 99 mm Hg) and no history of cardiovascular disease produces similar health benefits as treating patients with stage 2 hypertension (i.e., systolic measurement of 160 mm Hg or greater and/or diastolic measurement of 100 mm Hg or greater).
The authors identified four randomized controlled trials (RCTs) examining the clinical effectiveness of pharmacotherapy for mild hypertension in 8,912 participants (mean age range = 37 to 72 years) without previous cardiovascular events. Outcomes included overall mortality, total cardiovascular events (stroke, myocardial infarction, and congestive heart failure), and withdrawals from the trials because of adverse effects after four to five years of follow-up. Therapies included one or more of the following drugs: thiazide diuretics, beta blockers, reserpine, clonidine (Catapres), methyldopa, and hydralazine.
Meta-analysis showed no difference in overall mortality between the treatment and placebo groups (risk ratio [RR] = 0.85; 95% confidence interval [CI], 0.63 to 1.15). Pooled analysis of three RCTs (n = 7,080) demonstrated no difference in total cardiovascular events between the treatment and placebo groups (RR = 0.97; 95% CI, 0.72 to 1.32). One single-blinded RCT of 17,354 participants (mean age = 52 years) with mild to moderate hypertension demonstrated a statistically significant higher incidence of trial withdrawals because of adverse effects (RR = 4.80; 95% CI, 4.14 to 5.57) in the treatment group compared with the placebo group. The treatment group had a 9% risk of withdrawing from the study because of adverse effects. Authors rated the overall study quality as very low because of attrition bias, lack of clear reporting of randomization detail, and lack of investigator blinding in some RCTs; authors rated the one RCT examining withdrawals as moderate quality.
The lack of an observed treatment effect is not surprising, because patients with mild hypertension have a low baseline risk of cardiovascular disease events and overall mortality. Therefore, maximum benefit would be expected to be modest, at best, especially with a short follow-up window of four to five years.
The evidence-informed, consensus opinion–based Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends that all stages of hypertension be treated to a goal of less than 140/90 mm Hg, beginning with lifestyle modification. If this goal is not achieved, thiazide diuretics should be used as initial pharmacotherapy for most patients, alone or in combination with one of the other drug classes (i.e., angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers) that also have been shown to reduce one or more hypertensive complications in RCTs.2 However, in light of the findings of this Cochrane review, it would be reasonable to emphasize pharmacotherapy in patients with stage 2 hypertension and to emphasize lifestyle changes in patients with mild hypertension and no cardiovascular disease. Larger double-blinded RCTs in this population of patients with stage 1 hypertension are needed to clarify the potential long-term benefits of pharmacologic therapy.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD006742.
Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;(8):CD006742.
1. Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services Task Force. Am J Prev Med. 2003;25;(2):151–158.
2. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
These are summaries of reviews from the Cochrane Library.
The series coordinator for AFP is Corey D. Fogleman, MD, Lancaster General Hospital Family Medicine Residency, Lancaster, Pa.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2013 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Oct 15, 2020
Access the latest issue of American Family Physician